Androgen receptor overexpression in prostate cancer in type 2 diabetes
Conclusions We report elevated androgen receptor signaling and activity presumably due to altered insulin/IGF-1 receptors and decreased levels of protective estrogen receptor ligands in prostate cancer in men with diabetes. Our results reveal new insights why these patients have a worse prognosis. These findings provide the basis for future clinical trials to investigate treatment response in patients with prostate cancer and diabetes.
The objective was to assess this combination in a retrospective cohort of patients with advanced PCa.
Fight Aging! provides a weekly digest of news and commentary for thousands of subscribers interested in the latest longevity science: progress towards the medical control of aging in order to prevent age-related frailty, suffering, and disease, as well as improvements in the present understanding of what works and what doesn't work when it comes to extending healthy life. Expect to see summaries of recent advances in medical research, news from the scientific community, advocacy and fundraising initiatives to help speed work on the repair and reversal of aging, links to online resources, and much more. This content is...
CONCLUSIONS: Afro-Caribbean populations in French West Indies share the same major clinical and pathological risk factors of BCR after RP identified in other ethnic groups. Perioperative blood loss appears to be an additional and independent predictive factor of BCR. LEVEL OF PROOF: 4. PMID: 29789237 [PubMed - as supplied by publisher]
A 65-year-old man presented with locally advanced, high-risk prostate cancer. His medical history was remarkable for type 2 diabetes mellitus, and he was an active smoker with a 27 pack-year history.
International Journal of Cancer,Volume 0, Issue ja, -Not available-.
This article reviews the clinical questions and bottom-line answers from these studies. Blood pressure should be measured after a period of rest, using a bare arm, and orthostatic blood pressure is more predictive when measured after one minute of standing rather than three minutes. Intensive blood pressure lowering results in cardiovascular benefits but also renal harms in high-risk patients with an average age of 68 years. The initiation of a statin for primary prevention does not reduce cardiovascular events in adults 65 years or older. Sterile gloves do not reduce the risk of infection for common outpatient skin proced...
Biguanides were originally developed for the treatment of hyperglycemia and type 2 diabetes mellitus. Recently, the biguanides metformin and phenformin have been shown to exert potential anticancer effects in prostate cancer. We evaluated the anti-cancer efficacy and mechanism of IM176, a novel biguanide derivate drug on prostate cancer using prostate cancer cell lines and patient-derived castration-resistant prostate cancer cell lines.
Androgen-deprivation therapy (ADT) is important in the treatment of prostate cancer. However, the relationship between ADT and the risk of diabetes remains unclear, and the association between duration and types of ADT has not been fully investigated.AimTo examine the risk of developing type 2 diabetes mellitus (T2DM) in men who underwent ADT for prostate cancer.
Ozgur raises some relevant points regarding diabetes stratification, metformin treatment duration and hyperlipidemia evaluation. It is correct that due to the information available in the Ontario Diabetes Database through the Institute for Clinical Evaluative Sciences we were unable to separate patients into type 1 and type 2 diabetes groups. However, we excluded insulin users due to the greater amount of comorbidities associated with more severe diabetes and the evidence indicating that higher levels of insulin can contribute to prostate cancer progression and worse outcomes.
Two medtech titans are teaming up to market a software GPS solution to detect lung cancer. Medtronic and Royal Philips announced the partnership and unveiled the jointly developed LungGPS Patient Management Platform earlier this week. To date, lung cancer remains the No. 1 cancer killer in the world, accounting for more cancer deaths than breast, colon, and prostate cancer combined, according to statistics from the American Cancer Society. “From my perspective, I think both organizations realize that more needs to be done to help transform lung cancer from a death sentence or deadly diseases, to something that is mor...